GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Creative Medical Technology Holdings Inc (NAS:CELZ) » Definitions » EBITDA per Share

Creative Medical Technology Holdings (Creative Medical Technology Holdings) EBITDA per Share : $-3.87 (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Creative Medical Technology Holdings EBITDA per Share?

Creative Medical Technology Holdings's EBITDA per Share for the three months ended in Mar. 2024 was $-0.71. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.87.

During the past 3 years, the average EBITDA per Share Growth Rate was 81.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Creative Medical Technology Holdings's EBITDA per Share or its related term are showing as below:

CELZ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 66.6   Med: 81.3   Max: 85.9
Current: 81.3

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Creative Medical Technology Holdings was 85.90% per year. The lowest was 66.60% per year. And the median was 81.30% per year.

CELZ's 3-Year EBITDA Growth Rate is ranked better than
98.36% of 1281 companies
in the Biotechnology industry
Industry Median: 6 vs CELZ: 81.30

Creative Medical Technology Holdings's EBITDA for the three months ended in Mar. 2024 was $-1.01 Mil.

During the past 3 years, the average EBITDA Growth Rate was 46.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Creative Medical Technology Holdings was 46.00% per year. The lowest was -736.10% per year. And the median was -15.70% per year.


Creative Medical Technology Holdings EBITDA per Share Historical Data

The historical data trend for Creative Medical Technology Holdings's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Creative Medical Technology Holdings EBITDA per Share Chart

Creative Medical Technology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,280.50 -603.95 181.40 -9.29 -3.93

Creative Medical Technology Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.83 -1.06 -1.26 -0.71

Creative Medical Technology Holdings EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Creative Medical Technology Holdings's EBITDA per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA per Share(A: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-5.526/1.408
=-3.92

Creative Medical Technology Holdings's EBITDA per Share for the quarter that ended in Mar. 2024 is calculated as

EBITDA per Share(Q: Mar. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-1.012/1.421
=-0.71

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Creative Medical Technology Holdings  (NAS:CELZ) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Creative Medical Technology Holdings EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Creative Medical Technology Holdings's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Creative Medical Technology Holdings (Creative Medical Technology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid-derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
Executives
Timothy Warbington director, 10 percent owner, officer: President & CEO 211 E. OSBORN ROAD, PHOENIX AZ 85012
Michael H. Finger director 1551 N. DIANE ST., MESA AZ 85203-3850
Susan H Snow director 26 SEDGE FERN DRIVE, HILTON HEAD SC 29926
Bruce Steven Urdang director 5171 E. HAWTHORNE DR., FLAGSTAFF AZ 86004-7377
Thomas Ichim director 211 E. OSBORN RD, PHOENIX AZ 85012
Creative Medical Health Inc. 10 percent owner 211 E. OSBORN RD, PHOENIX AZ 85012
Timothy Herbst 10 percent owner 2031 W. PEORIA AVE., SUITE 250, PHOENIX AZ 85029
Amit Nilkanth Patel director 1040 CHARTWELL CT., SALT LAKE CITY UT 84121
Donald Dickerson director, officer: CFO & Sr.VP 822 VERA STREET, SOLANA BEACH CA 92075
Steven L White director, officer: President,Secretary,Treasurer 386 NORTH 210 EAST, MAPLETON UT 84664

Creative Medical Technology Holdings (Creative Medical Technology Holdings) Headlines

From GuruFocus